Combined venetoclax and alvocidib in acute myeloid leukemia

More effective treatment options for elderly acute myeloid leukemia (AML) patients are needed as only 25–50% of patients respond to standard-of-care therapies, response duration is typically short, and disease progression is inevitable even with some novel therapies and ongoing clinical trials. Anti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Bogenberger, James, Whatcott, Clifford, Hansen, Nanna, Delman, Devora, Shi, Chang-Xin, Kim, Wontak, Haws, Hillary, Soh, Katherine, Lee, Ye Sol, Peterson, Peter, Siddiqui-Jain, Adam, Weitman, Steven, Stewart, Keith, Bearss, David, Mesa, Ruben, Warner, Steven, Tibes, Raoul
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739808/
https://ncbi.nlm.nih.gov/pubmed/29291023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22284
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares